XERS שיעור רווח גולמי Xeris Biopharma Inc

סמל תאגידי ולוגו של Xeris Biopharma Holdings, Inc. (XERS)

Reliable injection delivery via temperature control ensures therapy readiness, and the base chart on GURU.Markets contains the gross profit percentage, where the latest parameter is 84.40. The Xeris Biopharma (XERS) model is based on alliances with biotech laboratories to create new formulas, while the company relies on standard environmental regulations for waste disposal and energy conservation.

Xeris Biopharma (XERS): שולי רווח גולמי מ-04.07.2022 עד 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור Xeris Biopharma Holdings, Inc. (XERS)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח בסיסי של החברה:Xeris Biopharma Holdings (XERS)
פריט של המותג Xeris Biopharma Holdings

Gross margin measures production efficiency by determining the portion of revenue remaining after covering direct costs of goods sold. The trend in gross margin allows investors to assess the pricing power of Xeris Biopharma (XERS) in the sale of specialized injection systems for patients with endocrine pathologies, whose expenses are covered by insurance payments.